Kinase Inhibitor [EPC]

542732 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS NILOTINIB GEFITINIB SORAFENIB PALBOCICLIB ACALABRUTINIB AXITINIB BOSUTINIB LAROTRECTINIB LORLATINIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 60590
1 FATIGUE 48472
2 DIARRHOEA 44879
3 OFF LABEL USE 38015
4 NAUSEA 30673
5 MALIGNANT NEOPLASM PROGRESSION 20276
6 ASTHENIA 19205
7 DECREASED APPETITE 18261
8 RASH 17878
9 VOMITING 17030
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 313 0.8505
1 ACQUIRED GENE MUTATION 677 0.5228
2 NEOPLASM PROGRESSION 16254 0.4715
3 TRYPTASE INCREASED 278 0.4131
4 CARBOHYDRATE ANTIGEN 15-3 INCREASED 252 0.3405
5 MYELOFIBROSIS 975 0.3316
6 METASTASES TO MENINGES 692 0.3193
7 HAEMATOCRIT ABNORMAL 370 0.3122
8 MANTLE CELL LYMPHOMA 434 0.2983
9 TUMOUR MARKER INCREASED 1356 0.2892
See all enriched reactions for Kinase Inhibitor [EPC]